lOMoARcPSD|58511717
NR546 W3 Antipsychotics Table
Nursing (Chamberlain University)
Scan to open on Studocu
Studocu is not sponsored or endorsed by any college or university
Downloaded by Samuel Kinyanjui ()
, lOMoARcPSD|58511717
Drug name Indication Notable side effects (associate to pathway or NT)
Target symptoms: state if positive or negative effect
Potency (if noted. receptor occupancy if noted )
Neurotransmitter(s) affected
Haloperidol Target symptoms: Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and vocal Akathisia
utterances in Tourette’s Syndrome Second-line Drug-induced parkinsonism
treatment of severe behavior problems in children of Tardive dyskinesia, dystonia
combative, explosive, hyperexcitability Secondline Irreversible involuntary dyskinetic movements
short-term treatment of hyperactive children Galactorrhea, amenorrhea
Treatment of schizophrenic patients who require Dizziness, sedation
prolonged parenteral antipsychotic therapy Bipolar Dry mouth
Disorder Behavioral disturbances in dementias Delirium Constipation
(with lorazepam) Positive symptoms of psychosis, Urinary retention
violent or aggressive behavior Blurred vision
Potency: High potency first-generation Decreased sweating
Neurotransmitter(s) affected: Blocks dopamine 2 Hypotension
receptors, reducing positive symptoms of psychosis and Tachycardia
combative, explosive, and hyperactive behaviors Blocks Hypertension
dopamine 2 receptors in the nigrostriatal pathway, Weight gain
improving tics and other symptoms in Tourette’s
syndrome
Thioridazine Target symptoms: Neuroleptic-induced deficit syndrome
Used for Schizophrenia in patients who fail to respond Akathisia
to treatment with other antipsychotic drugs Positive Priapism
symptoms of psychosis Motor and autonomic Drug-induced parkinsonism
hyperactivity Violent or aggressive behavior Tardive dyskinesia
Potency: Low-potency first-generation Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis Pigmentary retinopathy
Dizziness, sedation
Dry mouth
NR546 W3 Antipsychotics Table
Nursing (Chamberlain University)
Scan to open on Studocu
Studocu is not sponsored or endorsed by any college or university
Downloaded by Samuel Kinyanjui ()
, lOMoARcPSD|58511717
Drug name Indication Notable side effects (associate to pathway or NT)
Target symptoms: state if positive or negative effect
Potency (if noted. receptor occupancy if noted )
Neurotransmitter(s) affected
Haloperidol Target symptoms: Neuroleptic-induced deficit syndrome
Manifestations of psychotic disorders Tics and vocal Akathisia
utterances in Tourette’s Syndrome Second-line Drug-induced parkinsonism
treatment of severe behavior problems in children of Tardive dyskinesia, dystonia
combative, explosive, hyperexcitability Secondline Irreversible involuntary dyskinetic movements
short-term treatment of hyperactive children Galactorrhea, amenorrhea
Treatment of schizophrenic patients who require Dizziness, sedation
prolonged parenteral antipsychotic therapy Bipolar Dry mouth
Disorder Behavioral disturbances in dementias Delirium Constipation
(with lorazepam) Positive symptoms of psychosis, Urinary retention
violent or aggressive behavior Blurred vision
Potency: High potency first-generation Decreased sweating
Neurotransmitter(s) affected: Blocks dopamine 2 Hypotension
receptors, reducing positive symptoms of psychosis and Tachycardia
combative, explosive, and hyperactive behaviors Blocks Hypertension
dopamine 2 receptors in the nigrostriatal pathway, Weight gain
improving tics and other symptoms in Tourette’s
syndrome
Thioridazine Target symptoms: Neuroleptic-induced deficit syndrome
Used for Schizophrenia in patients who fail to respond Akathisia
to treatment with other antipsychotic drugs Positive Priapism
symptoms of psychosis Motor and autonomic Drug-induced parkinsonism
hyperactivity Violent or aggressive behavior Tardive dyskinesia
Potency: Low-potency first-generation Irreversible involuntary dyskinetic movements
Neurotransmitter(s) affected: Blocks dopamine 2 Galactorrhea, amenorrhea
receptors, reducing positive symptoms of psychosis Pigmentary retinopathy
Dizziness, sedation
Dry mouth
